1. Better Diabetes Control With Novel Basal Insulins

3. Program Overview

4. Why Next-Generation Basal Insulins Were Developed

5. Next-Generation Basal Insulins Currently Licensed

6. Patients Who Will Benefit Most From Next-Generation Basal Insulins

7. Benefits for Primary Care Physicians

8. Continuum of Clinical Research: RCTs and RWE

9. RCTs Do Not Represent Most Patients With T2DM

10. Summary of BEGIN and EDITION Trials in People With T2DM

11. BEGIN and EDITION Trials for Deg-100 and Gla-300

12. RWE for Gla-300: DELIVER Studies

13. Pragmatic Trials

14. Pragmatic Trials With Deg-100 and Gla-300

15. Comparing Deg-100 and Gla-300

16. BRIGHT: Head-To-Head Comparison of Gla-300 and Deg-100

17. BRIGHT: Study Endpoints and Glycemic Targets

18. BRIGHT: Baseline Characteristics

19. BRIGHT: Primary Endpoint: Glycemic Control

20. BRIGHT: FPG and SMBG Reduction

21. BRIGHT: 8-Point SMBG and Variability Profiles

22. BRIGHT: Anytime (24 h) Hypoglycemia

23. BRIGHT: Nocturnal (00:00 to 06:00 h) Hypoglycemia

24. BRIGHT: TEAEs

25. BRIGHT: Insulin Dosage and Body Weight Over 24 Weeks

26. BRIGHT: Results Summary

27. BRIGHT: Results Summary (cont)

28. BRIGHT: Key Messages for Primary Care

29. RWE for Second-Generation Basal Insulins

30. Limitations and Future of RWE

31. Conclusions

32. BRIGHT Study

33. Abbreviations

34. Abbreviations (cont)